← Back to Screener
DiaMedica Therapeutics Inc. Common Stock (DMAC)
Price$6.56
Favorite Metrics
Price vs S&P 500 (26W)-5.58%
Price vs S&P 500 (4W)-8.16%
Market Capitalization$369.10M
All Metrics
Book Value / Share (Quarterly)$0.99
P/TBV (Annual)42.56x
Indicated Dividend (Annual)$0.00
Cash Flow / Share (Quarterly)$-0.53
Price vs S&P 500 (YTD)-18.08%
EPS (TTM)$-0.72
10-Day Avg Trading Volume0.20M
EPS Excl Extra (TTM)$-0.72
EPS (Annual)$-0.60
ROI (Annual)-60.00%
Net Profit Margin (5Y Avg)-11188.60%
Cash / Share (Quarterly)$1.06
ROA (Last FY)-52.74%
EBITD / Share (TTM)$-0.71
ROE (5Y Avg)-43.82%
Cash Flow / Share (Annual)$-0.52
P/B Ratio7.15x
P/B Ratio (Quarterly)6.93x
Net Income / Employee (Annual)$-1
Net Interest Coverage (TTM)-143.97x
ROA (TTM)-73.52%
EPS Incl Extra (Annual)$-0.60
Current Ratio (Annual)8.28x
Quick Ratio (Quarterly)10.59x
3-Month Avg Trading Volume0.26M
52-Week Price Return97.41%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$0.38
P/S Ratio (Annual)738.19x
Asset Turnover (Annual)0.03x
52-Week High$10.42
Operating Margin (5Y Avg)-11740.00%
EPS Excl Extra (Annual)$-0.60
CapEx CAGR (5Y)65.72%
Tangible BV CAGR (5Y)-14.37%
26-Week Price Return3.16%
Quick Ratio (Annual)8.23x
13-Week Price Return-20.35%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)10.67x
Enterprise Value$365.786
Book Value / Share Growth (5Y)8.43%
Revenue / Employee (Annual)$0
Pretax Margin (Annual)-1130.80%
Cash / Share (Annual)$1.03
3-Month Return Std Dev55.47%
Net Income / Employee (TTM)$-1
ROE (Last FY)-60.03%
Net Interest Coverage (Annual)-49.10x
EPS Basic Excl Extra (Annual)$-0.60
Receivables Turnover (TTM)0.00x
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-0.72
Receivables Turnover (Annual)1.16x
ROI (TTM)-83.17%
Pretax Margin (5Y Avg)-11149.80%
Revenue / Share (Annual)$0.00
Tangible BV / Share (Annual)$0.38
Price vs S&P 500 (52W)62.31%
Year-to-Date Return-13.94%
5-Day Price Return8.73%
EPS Normalized (Annual)$-0.60
ROA (5Y Avg)-40.37%
Net Profit Margin (Annual)-1146.80%
Month-to-Date Return1.18%
Cash Flow / Share (TTM)$-0.61
EBITD / Share (Annual)$-0.60
Operating Margin (Annual)-1352.20%
LT Debt / Equity (Annual)0.01x
ROI (5Y Avg)-43.80%
LT Debt / Equity (Quarterly)0.01x
EPS Basic Excl Extra (TTM)$-0.72
P/TBV (Quarterly)42.56x
P/B Ratio (Annual)5.70x
Book Value / Share (Annual)$0.95
Price vs S&P 500 (13W)-23.21%
Beta1.11x
Revenue / Share (TTM)$0.00
ROE (TTM)-83.21%
52-Week Low$3.28
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.09
4.09
4.09
4.09
Industry Peers — Pharmaceuticals(309)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
DMACDiaMedica Therapeutics Inc. Common Stock | — | — | — | — | $6.56 |
LLYEli Lilly & Co. | 13.45x | 44.70% | 83.04% | 27.59% | $919.90 |
JNJJohnson & Johnson | 5.82x | 7.87% | 67.95% | 14.90% | $230.69 |
ABBVABBVIE INC. | 5.97x | 8.57% | 71.62% | -2.88% | $203.71 |
MRKMerck & Co., Inc. | 4.51x | 1.31% | 78.55% | 21.23% | $117.10 |
AZNAstraZeneca PLC | 5.39x | 8.63% | 81.31% | 21.88% | $200.69 |
NVSNovartis AG | 4.87x | 8.91% | 75.82% | 15.26% | $150.99 |
NVONovo-Nordisk A/S | 3.74x | 6.43% | 80.98% | 20.66% | $40.46 |
ABTAbbott Laboratories | 3.71x | 6.59% | 56.50% | 8.20% | $96.00 |
PFEPfizer Inc. | 2.50x | -1.64% | 75.81% | -3.51% | $27.52 |
BMYBristol-Myers Squibb Co. | 2.52x | -0.22% | 72.63% | — | $59.13 |
About
DiaMedica Therapeutics is a clinical-stage biopharmaceutical company developing therapies for ischemic diseases and acute pancreatitis. Its lead candidate, DM199, a recombinant human enzyme, is in clinical trials for acute ischemic stroke and preeclampsia. The company also develops DM300, a protease inhibitor being evaluated for severe acute pancreatitis.